Drug intelligence / Profile preview

BPM 31543

Development stage: Unknown
Lead developer: Berg
Modality: Small Molecules
Administration: Topical

Overview

BPM 31543 is a topical small molecule formulation of calcitriol (1,25-dihydroxyvitamin D3) developed by Berg Pharma for the prevention and treatment of chemotherapy-induced alopecia (CIA). As a Vitamin D receptor (VDR) agonist, the drug is designed to protect hair follicles from the cytotoxic effects of chemotherapy. The therapeutic mechanism involves modulating the hair follicle cycle, specifically by arresting the anagen (growth) phase, which is the phase most susceptible to damage from chemotherapy agents. BPM 31543 was evaluated in a Phase 1 dose-escalation study at Memorial Sloan-Kettering Cancer Center in adult patients with breast cancer, where it demonstrated safety and initial proof of concept for hair loss prevention.

Other names: topical calcitriol

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on BPM 31543.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPM 31543.

Explore the full profile